Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
January 26, 2004
- WEBSITE NEWS
January 26, 2004
- Target Approval Times for Ethical Drugs to Be Announced by April
January 26, 2004
- Korosho Studying Drug Review Update System
January 26, 2004
- Medical Expenses for 20 EBM GL-covered Diseases Account for 30% of Total, \7.3 Trillion
January 26, 2004
- Off-label Use of 15 Drugs to Be Reimbursed
January 26, 2004
- Korosho Calls For Withholding of Applications in March
January 26, 2004
- REGULATORY NEWS IN BRIEF
January 26, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 26, 2004
- BULLETIN
January 26, 2004
- NEW PRODUCTS
January 26, 2004
- 5 Top Products Exceed Sales of \30 Billion Each: PJ Survey
January 26, 2004
- Kyoto Univ. Invites Regional Med. Facilities to Clinical Study on ASO
January 26, 2004
- Tamiflu Should be Limited to Patients One Year of Age or Older
January 26, 2004
- OTC NEWS IN BRIEF
January 26, 2004
- Sumitomo, AstraZeneca Ink Joint Research Agreement for Respiratory Drugs
January 26, 2004
- MEDICAL DEVICE NEWS IN BRIEF
January 26, 2004
- FY 2004 Business Plan Approved: JPMA General Assembly
January 19, 2004
- BUSINESS NEWS IN BRIEF
January 19, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
January 19, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…